Disarming the Immune TRAP through a Targeted Antibody Removal Therapy to Prevent ICU-Acquired Infections and Reduce Antimicrobial Resistance

Healthcare-associated infections (HAIs) in intensive care units (ICUs) remain a major clinical and societal challenge. Up to 40% of ICU patients develop at least one infection, and mortality rates are often above 30%. The situation is further aggravated by the rise of antimicrobial resistance (AMR) and the declining effectiveness of existing antibiotics. Gram-negative pathogens are recognised by WHO as critical priority threats, with resistance to antibiotics projected to more than double by 2035. Current preventive strategies are insufficient and underscore the urgent need for novel biotech-based therapies.

DITRAP introduces RA0127, a first-in-class soluble glycopolymer that selectively removes natural anti-αGal antibodies. These antibodies, paradoxically, enhance Gram-negative infections and create an “immune trap” in critically ill patients. By disarming this trap, RA0127 strengthens host immunity without immunosuppression, restoring the body’s ability to clear even multidrug-resistant pathogens. A completed Phase 1 trial confirmed safety and demonstrated over 60% reduction of target antibodies after a single low dose, providing a strong foundation for Phase 2 evaluation.

To maximise precision and responsible clinical application, DITRAP integrates an AI-based stratification tool that identifies high-risk patients within 48 hours of admission and enables targeted therapy. Alongside, comprehensive health economic modelling and Health Technology Assessment (HTA) will ensure robust evaluation of clinical benefit, cost-effectiveness and adoption across European healthcare systems.

The consortium unites leading SMEs, clinical and academic partners with complementary expertise and are supported by the European Society of Anaesthesiology and Intensive Care (ESAIC). DITRAP directly addresses Horizon Europe’s objective to boost translation of biotech research into innovative therapies, advancing Europe’s fight against AMR and tackling an urgent public health priority.

This project is currently in grant preparation with the European Commission.

This project contributes to the UN Sustainable Development Goals (SDGs) 3 and 9.